A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection
Launched by HOFFMANN-LA ROCHE · Aug 30, 2001
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
Patients are randomized to one of four treatment arms. ddC is administered at 1 of 2 doses every 8 hours. AZT is administered at 1 of 2 doses (every 4 hours while awake or every 8 hours).
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HIV infection.
- • CD4 count 100 - 500 cells/mm3.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Chicago, Illinois, United States
Miami, Florida, United States
Miami, Florida, United States
Harbor City, California, United States
San Francisco, California, United States
Washington, District Of Columbia, United States
Wichita, Kansas, United States
Milwaukee, Wisconsin, United States
Galveston, Texas, United States
Dallas, Texas, United States
Los Angeles, California, United States
Boston, Massachusetts, United States
Brooklyn, New York, United States
Denver, Colorado, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Portland, Oregon, United States
Bronx, New York, United States
San Diego, California, United States
Washington, District Of Columbia, United States
Atlanta, Georgia, United States
St. Paul, Minnesota, United States
St. Louis, Missouri, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials